Clinical trials: Acute Phase
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345…
- Conditions
- SARS-CoV-2, Influenza, RSV
- Trial name
- NCT05585632
- Testing
- mRNA-1010, mRNA-1345, mRNA-1273.214
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Polycythemia Vera, Essential Thrombocythemia
A Study of GLB-001 in Patients With Myeloid Malignancies
Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
- Trial name
- NCT06378437
- Testing
- GLB-001
- Where
- 14 sites in China
- Volunteers
- 108 people
- Sponsor
- Hangzhou GluBio Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
AXIS 2: AX200 for the Treatment of Ischemic Stroke
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
- Trial name
- AXIS-2 (NCT00927836)
- Testing
- Filgrastim, Sodium chloride solution
- Where
- 58 sites in Austria, Belgium and 5 more
- Volunteers
- 328 people
- Sponsor
- Sygnis Bioscience GmbH & Co KG
Acute Ischemic Stroke, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics…
- Trial name
- ASSENT (NCT02586233)
- Testing
- DS-1040b
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- Daiichi Sankyo
Hamstring Muscle Strain, Skeletal Muscle Injury
BPC 157 for Acute Hamstring Muscle Strain Repair
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II…
- Trial name
- BPC-HAMSTR (NCT07437547)
- Testing
- Pentadecapeptide BPC 157
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech
Respiratory Distress Syndrome
Carperitide in Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study is to determine whether Carperitide is safe and effective in the management of Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT00030121
- Testing
- recombinant human atrial natriuretic polypeptide
- Sponsor
- Suntory Pharmaceutical
Stroke, Acute
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
The primary objectives of this study is to evaluate the efficacy of HLCM051 on functional outcome in subjects with acute ischemic stroke and to evaluate the safety of HLCM051 in subjects with acute ischemic stroke.
- Trial name
- TREASURE (NCT02961504)
- Testing
- HLCM051
- Where
- Japan
- Volunteers
- 206 people
- Sponsor
- Healios K.K.
T Cell Lymphoma, B Cell Lymphoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
- Conditions
- T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
- Trial name
- NCT06492304
- Testing
- CTX131
- Where
- 7 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- CRISPR Therapeutics
Myocardial Infarction
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
The purpose of the study is to determine whether adult stem cells [Provacel™(PUMP1)] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).
- Trial name
- NCT00114452
- Testing
- Provacel
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mesoblast, Inc.
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Congenital Fibrinogen Deficiency
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency
This study will assess the efficacy of Octafibrin, a fibrinogen concentrate in in the on-demand treatment of spontaneous or traumatic bleeding episodes in paediatric patients less than 12 years of age.The planned study duration…
- Trial name
- NCT02408484
- Testing
- Octafibrin
- Where
- 4 sites in India, Iran and 1 more
- Volunteers
- 15 people
- Sponsor
- Octapharma
Stroke
Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)
The purpose of this study was to explore trends in safety and efficacy, and to find the optimal dose for the subsequent phase III trial.
- Trial name
- DEDAS (NCT00638248)
- Testing
- Desmoteplase
- Volunteers
- 38 people
- Sponsor
- PAION Deutschland GmbH
Long COVID, Post-COVID-19 Condition
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome, Post-COVID Condition
- Trial name
- NCT07184385
- Testing
- REGENECYTE
- Volunteers
- 60 people
- Sponsor
- StemCyte, Inc.
Community-acquired Pneumonia
Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia
The purpose of this study is to determine the safety and efficacy of ONO-5046Na in patients with acute respiratory failure associated with community-acquired pneumonia
- Trial name
- NCT00417326
- Testing
- ONO-5046Na
- Where
- 9 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Coronavirus, Covid19
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04860258
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 129 people
- Sponsor
- CureVac
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT04872478
- Testing
- MRX-2843
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Meryx, Inc.
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03733249
- Testing
- Rimiducid, rivogenlecleucel
- Where
- Italy
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT07387926
- Testing
- Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone
- Where
- 4 sites in Australia, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial
This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with…
- Trial name
- NCT06447415
- Testing
- HRS-7450, 0.9% sodium chloride injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
This project is an open, dose escalation and expansion phase I clinical study. The first phase is a dose escalation study, and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended…
- Trial name
- NCT05426798
- Testing
- TQB2618 injection azacitidine, AZA decitabine, DAC
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.